rich online slots game 777

NoneAMD's Ryzen X3D processors are some of the hottest on the market, and the newest and hottest of all is the Ryzen 7 9800X3D. The first 9000-series chip with extra V-cache for gaming desktops was a smash hit right out of the gate, selling out almost immediately — so if you're hunting for one this holiday season, beware of deals that are too good to be true. The 9800X3D has a retail price of $479, if you can actually find one in a store or an online shop that still has stock. Sellers on eBay are easily getting $600+ for a quick flip, and that seems likely to persist for the rest of the year and into next year. But a few shoppers... Michael Crider

Cue plenty of ridiculous hand-wringing and moralising in the west over a decision Fifa made months ago, and no one in a position to do so did anything to stop. Sport generally long since abandoned any morale high ground it might have once occupied, while football is generations removed from having any right to tell people how to behave. Meanwhile, the tournament in 2030 will be hosted by Spain, Portugal, Morocco, Argentina, Paraguay, and Uruguay. The last of those staged the first World Cup in 1930, when the game was what mattered. How times have changed. The question Manchester City fans have to be asking themselves right now isn’t, when will the team win again, but how bad can it get? Pretty bad if the 2-0 loss away at Juventus in the latest round of Champions League matches is any indication. Pep Guardiola’s side did not have a shot on target until just before half-time, when Erling Haaland’s effort was saved by Michele di Gregorio. They have won just one of their last 10 games in all competitions, with this their seventh loss during that run. It all went wrong for the visitors after the break, with Dusan Vlahovic’s header and Weston McKennie’s volley securing all three points for the Italians. While Juventus boosted their own hopes of progressing automatically to the next stage as one of the top eight sides in the league phase of the competition, defeat left City 22nd with just two games remaining. They need to be in the top 24 to have a chance of reaching the next round. Bukayo Saka scored twice as Arsenal beat Monaco 3-0 to strengthen their position as one of the sides likely to progress to the knockout stages of the Champions League.House approves $895B defense bill with military pay raise, ban on transgender care for minorsTORONTO--(BUSINESS WIRE)--Dec 6, 2024-- Greenland Resources Inc. (Cboe CA: MOLY | FSE: M0LY) (“Greenland Resources” or the “Company”) welcomes the Government of Canada’s decision announced today to appoint an Arctic ambassador and open a consulate in Nuuk, Greenland. This follows the new Canadian Arctic Foreign Policy Framework to protect, together with its allies, the economic and military challenges including mineral resources security supply in the Arctic. The Company believes this is relevant for the Project as it is in negotiations to secure Capex funding from Canadian and recently announced European financial institutions and agencies in its press releases dated October 1 and October 15, 2024 . This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241206778181/en/ Greenland Resources Inc. Greenland Resources is a Canadian public company with the Ontario Securities Commission as its principal regulator and is focused on the development of its 100% owned Climax type primary molybdenum deposit located in central east Greenland. The Project has copper and also magnesium, a market dominated 98% by China. The Malmbjerg molybdenum project is an open pit operation with an environmentally friendly mine design focused on reduced water usage, low aquatic disturbance and low footprint due to modularized infrastructure. The Malmbjerg project benefits from an NI 43-101 Definitive Feasibility Study completed by Tetra Tech in 2022, with an US$820 million capex and a levered after-tax IRR of 33.8% and payback of 2.4 years, using US$18 per pound molybdenum price. The Proven and Probable Reserves are 245 million tonnes at 0.176% MoS 2, for 571 million pounds of contained molybdenum metal. As the high-grade molybdenum is mined for the first half of the mine life, the average annual production for years one to ten is 32.8 million pounds per year of contained molybdenum metal at an average grade of 0.23% MoS 2, approximately 25% of EU total yearly consumption. The project had a previous exploitation license granted in 2009. With offices in Toronto, the Company is led by a management team with an extensive track record in the mining industry and capital markets. For further details, please refer to our web site ( www.greenlandresources.ca ) and our Canadian regulatory filings on Greenland Resources’ profile at www.sedarplus.com . The Project is supported by the European Raw Materials Alliance (ERMA). ERMA is managed by EIT RawMaterials , an organization within the EIT, a body of the European Union. About Molybdenum and the European Union Molybdenum is a critical metal used mainly in steel and chemicals that is needed in all technologies in the upcoming green energy transition. When added to steel and cast iron, it enhances strength, hardenability, weldability, toughness, temperature strength, and corrosion resistance. Based on data from the International Molybdenum Association and the European Commission Steel Report, the world produced around 576 million pounds of molybdenum in 2021 where the European Union (“EU”) as the second largest steel producer in the world used approximately 24% of global molybdenum supply and has no domestic molybdenum production. To a greater degree, the EU steel dependent industries like the automotive, construction, and engineering, represent around 18% of the EU’s ≈ US$16 trillion GDP. Greenland Resources strategically located Malmbjerg molybdenum project has the potential to supply in and for the EU approximately 25% of the EU consumption, of environmentally friendly high-quality molybdenum from a responsible EU Associate country, for decades to come. The high quality of the Malmbjerg ore, having low impurity content in phosphorus, tin, antimony, and arsenic, makes it an ideal source of molybdenum for the high-performance steel industry lead worldwide by Europe, specifically the Scandinavian countries and Germany. Forward Looking Statements This news release contains "forward-looking information" (also referred to as "forward looking statements"), which relate to future events or future performance and reflect management’s current expectations and assumptions. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "hopes", "expects", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates", or "believes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Such forward-looking statements reflect management’s current beliefs and are based on assumptions made by and information currently available to the Company. All statements, other than statements of historical fact, are forward-looking statements or information. Forward-looking statements or information in this news release relate to, among other things: the Company’s objectives, goals or future plans; planned capex financing and outcomes of due diligence reviews; construction and engineering initiatives for the Malmbjerg molybdenum project; statements, exploration results, potential mineralization, the estimation of mineral resources and reserves, and their valuation, exploration and mine development plans, timing of the commencement of operations and estimates of market conditions. These forward-looking statements and information reflect the Company’s current views with respect to future events and are necessarily based upon a number of assumptions that, while considered reasonable by the Company, are inherently subject to significant operational, business, economic and regulatory uncertainties and contingencies. These assumptions include: future planned development and other activities on the Project; favourable outcomes of due diligence reviews; planned energy requirements of the Project; obtaining the permitting on the Project in a timely manner; no adverse changes to the planned operations of the Project; continued favourable relationships with local communities; current EU and other initiatives remaining in place into the future; expected demand for molybdenum in the EU and abroad, including by companies that expressed an interest in purchasing molybdenum; our mineral reserve estimates and the assumptions upon which they are based, including geotechnical and metallurgical characteristics of rock confirming to sampled results and metallurgical performance; tonnage of ore to be mined and processed; ore grades and recoveries; assumptions and discount rates being appropriately applied to the technical studies; estimated valuation and probability of success of the Company’s projects, including the Malmbjerg molybdenum project; prices for molybdenum remaining as estimated; currency exchange rates remaining as estimated; availability of funds for the Company’s projects; capital decommissioning and reclamation estimates; mineral reserve and resource estimates and the assumptions upon which they are based; prices for energy inputs, labour, materials, supplies and services (including transportation); no labour-related disruptions; no unplanned delays or interruptions in scheduled construction and production; all necessary permits, licenses and regulatory approvals are received in a timely manner or at all; and the ability to comply with environmental, health and safety laws. The foregoing list of assumptions is not exhaustive. The Company cautions the reader that forward-looking statements and information include known and unknown risks, uncertainties and other factors that may cause actual results and developments to differ materially from those expressed or implied by such forward-looking statements or information contained in this news release and the Company has made assumptions and estimates based on or related to many of these factors. Such factors include, without limitation: the favourable results of the SIA (Social Impact Assessment) and EIA (Environmental Impact Assessment); favourable local community support for the Project’s development; the projected demand for molybdenum both in the EU and elsewhere, including by companies that expressed an interest in purchasing molybdenum; the current initiatives and programs for resource development in the EU and abroad; the projected and actual status of supply chains, labour market, currency and commodity prices interest rates and inflation; the projected and actual status of the global and Canadian capital markets, fluctuations in molybdenum and commodity prices; fluctuations in prices for energy inputs, labour, materials, supplies and services (including transportation); fluctuations in currency markets (such as the Canadian dollar versus the U.S. dollar versus the Euro); operational risks and hazards inherent with the business of mining (including environmental accidents and hazards, industrial accidents, equipment breakdown, unusual or unexpected geological or structure formations, cave-ins, flooding and severe weather); inadequate insurance, or the inability to obtain insurance, to cover these risks and hazards; our ability to obtain all necessary permits, licenses and regulatory approvals in a timely manner; changes in laws, regulations and government practices in Greenland, including environmental, export and import laws and regulations; legal restrictions relating to mining; risks relating to expropriation; increased competition in the mining industry for equipment and qualified personnel; the availability of additional capital; title matters and the additional risks identified in our filings with Canadian securities regulators on SEDAR+ in Canada (available at www.sedarplus.ca ). Although the Company has attempted to identify important factors that could cause actual results to differ materially, there may be other factors that cause results not to be as anticipated, estimated, described, or intended. Investors are cautioned against undue reliance on forward-looking statements or information. These forward-looking statements are made as of the date hereof and, except as required by applicable securities regulations, the Company does not intend, and does not assume any obligation, to update the forward-looking information. Neither the Cboe Canada Exchange nor its regulation services provider accepts responsibility for the adequacy of this release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein. View source version on businesswire.com : https://www.businesswire.com/news/home/20241206778181/en/ CONTACT: Ruben Shiffman, PhD Chairman, President Keith Minty, P.Eng, MBA Engineering and Project Management Jim Steel, P.Geo, MBA Exploration and Mining Geology Nauja Bianco, M.Pol.Sci. Public and Community Relations Gary Anstey Investor Relations Eric Grossman, CPA, CGA Chief Financial Officer Corporate office Suite 1810, 25 York Street, Toronto, Ontario, Canada M5J 2V5 1-844-252-0532 info@greenlandresourcesinc.com www.greenlandresources.ca KEYWORD: IRELAND UNITED KINGDOM GREENLAND CANADA NORTH AMERICA EUROPE INDUSTRY KEYWORD: PUBLIC POLICY/GOVERNMENT DEFENSE MINING/MINERALS OTHER POLICY ISSUES MILITARY NATURAL RESOURCES SOURCE: Greenland Resources Inc. Copyright Business Wire 2024. PUB: 12/06/2024 02:07 PM/DISC: 12/06/2024 02:05 PM http://www.businesswire.com/news/home/20241206778181/en

Texans foiled by mistake after mistake in 32-27 loss to Titans

Alphabet Inc. (NASDAQ:GOOGL) Shares Sold by FMB Wealth Management

GSG Advisors LLC Acquires 753 Shares of Alphabet Inc. (NASDAQ:GOOGL)

At a town hall meeting with the bureau workforce, Mr Wray said he would be stepping down “after weeks of careful thought”. Mr Wray’s intended resignation is not unexpected considering that Mr Trump had picked Mr Patel for the role in his new administration. Mr Wray had previously been named by Mr Trump and began the 10-year term — a length meant to insulate the agency from the political influence of changing administrations — in 2017, after Mr Trump fired then-FBI director James Comey. Mr Trump had demonstrated his anger with Mr Wray on multiple occasions, including after Mr Wray’s congressional testimony in September. “My goal is to keep the focus on our mission — the indispensable work you’re doing on behalf of the American people every day,” Mr Wray told agency employees. “In my view, this is the best way to avoid dragging the bureau deeper into the fray, while reinforcing the values and principles that are so important to how we do our work.” Mr Wray continued: “It should go without saying, but I’ll say it anyway — this is not easy for me. I love this place, I love our mission, and I love our people — but my focus is, and always has been, on us and doing what’s right for the FBI.” Mr Wray received a standing ovation following his remarks before a standing-room-only crowd at FBI headquarters and some in the audience cried, according to an FBI official who was not authorised to discuss the private gathering and spoke on condition of anonymity to The Associated Press. Mr Trump applauded the news on social media, calling it “a great day for America as it will end the weaponisation of what has become known as the United States Department of Injustice” and saying that Mr Patel’s confirmation will begin “the process of Making the FBI Great Again”. If confirmed by the Senate, Mr Patel would herald a radical leadership transformation at the nation’s premier federal law enforcement agency. He has advocated shutting down the FBI’s Washington headquarters and called for ridding the federal government of “conspirators”, raising alarm that he might seek to wield the FBI’s significant investigative powers as an instrument of retribution against Mr Trump’s perceived enemies. Mr Patel said in a statement Wednesday that he was looking forward to “a smooth transition. I will be ready to serve the American people on day one”.The health ministry in Hamas-run Gaza said Friday hospitals have only two days' fuel left before they must restrict services, after the UN warned aid delivery to the war-devastated territory is being crippled. The warning came a day after the International Criminal Court issued arrest warrants for Israeli Prime Minister Benjamin Netanyahu and former defence minister Yoav Gallant more than a year into the Gaza war. The United Nations and others have repeatedly decried humanitarian conditions, particularly in northern Gaza where Israel said Friday it had killed two commanders involved in Hamas's October 7, 2023 attack that triggered the war. Gaza medics said an overnight Israeli raid on Beit Lahia and nearby Jabalia resulted in dozens killed or missing. Marwan al-Hams, director of Gaza's field hospitals, told reporters all hospitals in the Palestinian territory "will stop working or reduce their services within 48 hours due to the occupation's (Israel's) obstruction of fuel entry". World Health Organization chief Tedros Adhanom Ghebreyesus said Friday he was "deeply concerned about the safety and well-being of 80 patients, including 8 in the intensive care unit" at Kamal Adwan hospital, one of just two partly operating in northern Gaza. Late Thursday, the UN's humanitarian coordinator for the Palestinian territories, Muhannad Hadi, said: "The delivery of critical aid across Gaza, including food, water, fuel and medical supplies, is grinding to a halt." He said that for more than six weeks Israeli authorities "have been banning commercial imports" while "a surge in armed looting" has targeted aid convoys. Vowing to stop Hamas from regrouping, Israel on October 6 began an air and ground operation in Jabalia and then expanded it to Beit Lahia. Gaza's health ministry says the operation has killed thousands. The UN says more than 100,000 have been displaced from the area, and an official told the Security Council last week that people "are effectively starving". Issuing the warrants for Netanyahu and Gallant, the Hague-based ICC said there were "reasonable grounds" to believe they bore "criminal responsibility" for the war crime of starvation as a method of warfare, and crimes against humanity including over "the lack of food, water, electricity and fuel, and specific medical supplies". A furious Netanyahu said: "Israel rejects with disgust the absurd and false actions and accusations made against it." He said the judges were "driven by anti-Semitic hatred of Israel". On Friday, he thanked his Hungarian counterpart Viktor Orban for his show of "moral clarity" in inviting him to visit in defiance of the ICC warrant, which Orban branded "political". Hungary currently holds the rotating EU presidency. US President Joe Biden, whose country is Israel's top military supplier, called the warrants against Israeli leaders "outrageous", but other world leaders supported the court. Irish Prime Minister Simon Harris said Netanyahu would be arrested if he set foot in the country. Biden and French President Emmanuel Macron on Friday discussed efforts towards a ceasefire in Lebanon, the White House said. The ICC also issued a warrant for Hamas military chief Mohammed Deif, saying it had grounds to suspect him of war crimes and crimes against humanity over the attacks on Israel that sparked the war, and including "sexual and gender-based violence" against hostages. Israel said it killed Deif in July, but Hamas has not confirmed his death. On Thursday, a UN representative said an Israeli raid on Palmyra in Syria this week was "likely the deadliest" by Israel on the country so far. On Friday, a war monitor said the strikes killed 92 pro-Iran fighters. Israel again bombed Gaza on Friday. In Gaza City, just south of Jabalia, one man who said he took his cousins to hospital after a strike urged "the world... to put an end" to the war. Belal, who gave only his first name, said 10 members of his family had been killed. At least 44,056 people have been killed in Gaza during more than 13 months of war, most of them civilians, according to figures from Gaza's health ministry which the United Nations considers reliable. Hamas triggered the war with the deadliest attack in Israeli history, which resulted in the deaths of 1,206 people, mostly civilians, according to an AFP tally of Israeli official figures. The war expanded to Lebanon in late September when Israel escalated air strikes against Iran-backed Hezbollah and later sent ground troops into southern Lebanon, after nearly a year of tit-for-tat cross-border exchanges which Hezbollah said were in support of Hamas. Lebanon says more than 3,580 people have been killed in the country, most of them since late September. Israeli strikes again targeted Hezbollah's south Beirut stronghold and south Lebanon on Friday, the official National News Agency said. Thousands of UN peacekeepers are based in southern Lebanon and have reported coming under attack numerous times, blaming both Israel and "non-state" actors. On Friday, Italian Foreign Minister Antonio Tajani said Hezbollah was probably behind a rocket attack that lightly wounded four Italian peacekeepers. bur-ami/srm/kirThe Director, Directorate of General Studies at the Nigerian Defence Academy, Kaduna, Kaduna state, Prof. Zakaree Saheed, has called for the application of strategic management expertise to address Nigeria’s persistent socio-economic challenges. He spoke Thursday night in Abuja night at the Annual Corporate Dinner 2024, organised by the Nigerian Institute of Management (Chartered), Maitama Chapter, Abuja. Speaking on the theme “Managing Uncertainty: Leveraging Management Expertise in Overcoming Socio-economic Challenges,” Saheed noted the country’s struggles with infrastructure, unemployment, poverty, insecurity, and political instability. He argued that a strategic application of management expertise organising, coordinating, and optimising resources is key to overcoming these challenges. He stressed the importance of human capital development, particularly in Nigeria’s youthful population, and the need for education reform. Saheed said, “Nigeria remains the largest economy in Africa, endowed with significant natural and human resources. Yet, it continues to grapple with inadequate infrastructure, low industrial productivity, and challenging business environments. There are compounding multifaceted socio-economic issues, such as high unemployment, deficits in education, rising poverty, and insecurity stemming from insurgency and poor governance. “These problems erode public confidence and economic stability, further escalated by political instability, which creates a climate of uncertainty for policymakers, businesses, and individuals. “We need to address the root causes of these problems before we can find lasting solutions. This requires a strategic application of management expertise to navigate a sustainable path forward. By management expertise, I mean the ability to organise, coordinate, and optimise resources to achieve desired outcomes. “I believe that a clearly defined vision and mission form the foundation of policy formation and the establishment of a national agenda. If we know what we want -whether it is to become a technology-driven society, an educational hub, or an agricultural powerhouse – based on that, we can establish a national agenda,” he said. The chairman of the Maitama Chapter, Engr. Abdul Lawal Zubair, said the dinner provided an opportunity to connect and reflect, as it collectively advances the principles and values of effective management across all sectors of the nation. “As we enjoy the evening’s agenda, from insightful presentations and captivating performances to a delightful dining experience, let us also take this moment to strengthen the bonds that unite us as professional managers and ambassadors of excellence.”

Clinical and regulatory success in 2024 expected to drive value in 2025 CRANFORD, N.J. , Dec. 27, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal full year ended September 30, 2024 . Fiscal Full Year 2024 Business Highlights and Subsequent Developments Achieved U.S. Food and Drug Administration (FDA) approval of LYMPHIRTM (denileukin diftitox-cxdl), an immunotherapy for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL); Advanced manufacturing, marketing and sales activities in preparation for commercial launch of LYMPHIR in the first half of 2025; Completed the merger of Citius Pharma's oncology subsidiary with TenX Keane to form Citius Oncology, Inc., a standalone publicly traded company which began trading on the Nasdaq exchange under the ticker symbol CTOR on August 13, 2024 ; Supported two investigator-initiated trials to explore LYMPHIR's potential as an immuno-oncology combination therapy being conducted at the University of Pittsburgh Medical Center and the University of Minnesota ; Shared interim trial results with the clinical community at the Society for Immunotherapy of Cancer Conference (SITC) of University of Pittsburgh Medical Center's Phase I trial of LYMPHIR with checkpoint inhibitor pembrolizumab; and, Met primary and secondary endpoints in the Phase 3 Pivotal Trial of Mino-Lok ® , demonstrating a statistically significant improvement in time to catheter failure of infected catheters compared to other physician-selected anti-infective lock solutions. Financial Highlights Cash and cash equivalents of $3.3 million as of September 30, 2024 ; R&D expenses were $11.9 million for the full year ended September 30, 2024 , compared to $14.8 million for the full year ended September 30, 2023 ; G&A expenses were $18.2 million for the full year ended September 30, 2024 , compared to $15.3 million for the full year ended September 30, 2023 ; Stock-based compensation expense was $11.8 million for the full year ended September 30, 2024 , compared to $6.6 million for the full year ended September 30, 2023 ; and, Net loss was $39.4 million , or ($5.97) per share for the full year ended September 30, 2024 compared to a net loss of $32.5 million , or ($5.57) per share for the full year ended September 30, 2023 . "In fiscal year 2024 we drove tremendous progress in our pipeline. It was a transformative year, marked by our first FDA approval and significant clinical milestones. The approval of LYMPHIRTM and the positive Phase 3 results for Mino-Lok® underscore our commitment to developing innovative therapies. Our team successfully responded to FDA comments related to the biologics license application for LYMPHIR and ultimately gained FDA approval. Productive engagement with the FDA regarding the positive results of our Phase 3 Mino-Lok® trial and Phase 2 Halo-Lido trial clarified our next steps for both programs. We anticipate continued engagement with the agency in the coming year and look forward to their guidance. Additionally, we are exploring strategic partnerships and licensing opportunities to maximize the potential of our portfolio and bring these important therapies to market efficiently," stated Leonard Mazur , Chairman and CEO of Citius Pharma. "Looking ahead, our priorities for fiscal year 2025 include launching LYMPHIRTM through our majority-owned subsidiary, Citius Oncology, driving the clinical and regulatory strategies for Mino-Lok® and Halo-Lido, fortifying our financial position, and applying a disciplined approach to resource allocation. We expect to launch LYMPHIR in the first half of 2025 and distribute CTOR shares to Citius Pharma shareholders by the end of the year, pending favorable market conditions. Our goal remains to deliver value for patients, healthcare providers, and shareholders. With a clear vision and a strong team, we are well-positioned to execute on our mission of bringing innovative therapies to market," added Mazur. FULL YEAR 2024 FINANCIAL RESULTS: Liquidity As of September 30, 2024 , the Company had $3.3 million in cash and cash equivalents. As of September 30, 2024 , the Company had 7,247,243 common shares outstanding, as adjusted for the 1-for-25 reverse stock split of the Company's common stock, effected on November 25, 2024 . During the year ended September 30, 2024 , the Company received net proceeds of $13.8 million from the issuance of equity. The Company expects to raise additional capital to support operations. Research and Development (R&D) Expenses R&D expenses were $11.9 million for the full year ended September 30, 2024 , compared to $14.8 million for the full year ended September 30, 2023 . The decrease in R&D expenses primarily reflects the completion of the Halo-Lido trial and completion of activities related to the regulatory resubmission for LYMPHIR, offset by shutdown costs associated with the end of the Phase 3 trial for Mino-Lok. We expect research and development expenses to decrease in fiscal year 2025 as we continue to focus on the commercialization of LYMPHIR through our majority-owned subsidiary, Citius Oncology and because we have completed the Phase 3 trial for Mino-Lok. General and Administrative (G&A) Expenses G&A expenses were $18.2 million for the full year ended September 30, 2024 , compared to $15.3 million for the full year ended September 30, 2023 . The increase was primarily due to costs associated with pre-launch and market research activities associated with LYMPHIR. General and administrative expenses consist primarily of compensation costs, professional fees for legal, regulatory, accounting and corporate development services, and investor relations expenses. Stock-based Compensation Expense For the full year ended September 30, 2024 , stock-based compensation expense was $11.8 million as compared to $6.6 million for the prior year. The increase of $5.2 million is largely due to the grant of options under the Citius Oncology stock plan. Stock-based compensation expense under the Citius Oncology stock plan was $7.5 million during the year ended September 30, 2024 , compared to $2.0 million for the year ended September 30, 2023 , as the plan was initiated in July 2023 . For the years ended September 30, 2024 and 2023, stock-based compensation expense also includes $47,547 and $130,382 , respectively, for the NoveCite stock option plan. In fiscal years 2023 and 2024, we granted options to our new employees and additional options to other employees, our directors, and consultants. Net loss Net loss was $39.4 million , or ($5.97) per share for the year ended September 30, 2024 , compared to a net loss of $32.5 million , or ($5.57) per share for the year ended September 30, 2023 , as adjusted for the reverse stock split. The increase in net loss reflects an increase in operating expense of $5.3 million offset by a decrease of $1.6 million in other income. Operating expense increased due to increases in stock-based compensation and general and administrative expenses, which were offset by decreased research and development expense. About Citius Pharmaceuticals, Inc. Citius Pharma is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. In August 2024 , the FDA approved LYMPHIRTM, a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Citius Pharma's late-stage pipeline also includes Mino-Lok®, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections, and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. A Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial for Halo-Lido were completed in 2023. Mino-Lok met primary and secondary endpoints of its Phase 3 Trial. Citius Pharma is actively engaged with the FDA to outline next steps for both programs. For more information, please visit www.citiuspharma.com . Forward-Looking Statements This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius Pharma. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "plan," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated, and, unless noted otherwise, that apply to Citius Pharma are: our ability to raise additional money to fund our operations for at least the next 12 months as a going concern; our ability to commercialize LYMPHIR through our majority-owned subisity and any of our other product candidates that may be approved by the FDA; the estimated markets for our product candidates and the acceptance thereof by any market; the ability of our product candidates to impact the quality of life of our target patient populations; risks related to research using our assets but conducted by third parties; risks relating to the results of research and development activities, including those from our existing and any new pipeline assets; our ability to maintain compliance with Nasdaq's continued listing standards; our dependence on third-party suppliers; our ability to procure cGMP commercial-scale supply; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; the early stage of products under development; market and other conditions; risks related to our growth strategy; patent and intellectual property matters; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; government regulation; competition; as well as other risks described in our Securities and Exchange Commission ("SEC") filings. These risks have been and may be further impacted by any future public health risks. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our SEC filings which are available on the SEC's website at www.sec.gov , including in Citius Pharma's Annual Report on Form 10-K for the year ended September 30, 2024 , filed with the SEC on December 27, 2024 , as updated by our subsequent filings with the SEC. These forward-looking statements speak only as of the date hereof, and we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law. Investor Contact: Ilanit Allen ir@citiuspharma.com 908-967-6677 x113 Media Contact: STiR-communications Greg Salsburg Greg@STiR-communications.com -- Financial Tables Follow – CITIUS PHARMACEUTICALS, INC. CONSOLIDATED BALANCE SHEETS SEPTEMBER 30, 2024 AND 2023 2024 2023 ASSETS Current Assets: Cash and cash equivalents $ 3,251,880 $ 26,480,928 Inventory 8,268,766 — Prepaid expenses 2,700,000 7,889,506 Total Current Assets 14,220,646 34,370,434 Property and equipment, net — 1,432 Operating lease right-of-use asset, net 246,247 454,426 Other Assets: Deposits 38,062 38,062 In-process research and development 92,800,000 59,400,000 Goodwill 9,346,796 9,346,796 Total Other Assets 102,184,858 68,784,858 Total Assets $ 116,651,751 $ 103,611,150 LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities: Accounts payable $ 4,927,211 $ 2,927,334 License payable 28,400,000 — Accrued expenses 17,027 476,300 Accrued compensation 2,229,018 2,156,983 Operating lease liability 241,547 218,380 Total Current Liabilities 35,814,803 5,778,997 Deferred tax liability 6,713,800 6,137,800 Operating lease liability – non current 21,318 262,865 Total Liabilities 42,549,921 12,179,662 Commitments and Contingencies Stockholders' Equity: Preferred stock - $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding — — Common stock - $0.001 par value; 16,000,000 shares authorized; 7,247,243 and 6,354,371 shares issued and outstanding at September 30, 2024 and 2023, respectively 7,247 6,354 Additional paid-in capital 271,440,421 253,056,133 Accumulated deficit (201,370,218) (162,231,379) Total Citius Pharmaceuticals, Inc. Stockholders' Equity 70,077,450 90,831,108 Non-controlling interest 4,024,380 600,380 Total Equity 74,101,830 91,431,488 Total Liabilities and Equity $ 116,651,751 $ 103,611,150 Reflects a 1-for-25 reverse stock split effective November 25, 2024. CITIUS PHARMACEUTICALS, INC. CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE YEARS ENDED SEPTEMBER 30, 2024 AND 2023 2024 2023 Revenues $ — $ — Operating Expenses: Research and development 11,906,601 14,819,729 General and administrative 18,249,402 15,295,584 Stock-based compensation – general and administrative 11,839,678 6,616,705 Total Operating Expenses 41,995,681 36,732,018 Operating Loss (41,995,681) (36,732,018) Other Income: Interest income, net 758,000 1,179,417 Gain on sale of New Jersey net operating losses 2,387,842 3,585,689 Total Other Income Net 3,145,842 4,765,106 Loss before Income Taxes (38,849,839) (31,966,912) Income tax expense 576,000 576,000 Net Loss (39,425,839) (32,542,912) Net loss attributable to non-controlling interest 287,000 - Deemed dividend on warrant extension (1,047,312) (1,151,208) Net Loss Applicable to Common Stockholders $ (40,186,151) (33,694,120) Net Loss Per Share Applicable to Common Stockholders - Basic and Diluted $ (5.97) (5.57) Weighted Average Common Shares OutstandingBy HALELUYA HADERO, Associated Press President-elect Donald Trump asked the Supreme Court on Friday to pause the potential TikTok ban from going into effect until his administration can pursue a “political resolution” to the issue. The request came as TikTok and the Biden administration filed opposing briefs to the court, in which the company argued the court should strike down a law that could ban the platform by Jan. 19 while the government emphasized its position that the statute is needed to eliminate a national security risk. Related Articles “President Trump takes no position on the underlying merits of this dispute. Instead, he respectfully requests that the Court consider staying the Act’s deadline for divestment of January 19, 2025, while it considers the merits of this case,” said Trump’s amicus brief, which supported neither party in the case. The filings come ahead of oral arguments scheduled for Jan. 10 on whether the law, which requires TikTok to divest from its China-based parent company or face a ban, unlawfully restricts speech in violation of the First Amendment. Earlier this month, a panel of three federal judges on the U.S. Court of Appeals for the District of Columbia Circuit unanimously upheld the statute , leading TikTok to appeal the case to the Supreme Court. The brief from Trump said he opposes banning TikTok at this junction and “seeks the ability to resolve the issues at hand through political means once he takes office.”

outboundIQ Achieves Certified Implementation Partner (CIP) Status with Five9Principal Financial Group Inc. purchased a new stake in shares of Kinetik Holdings Inc. ( NASDAQ:KNTK – Free Report ) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 20,346 shares of the company’s stock, valued at approximately $921,000. Other hedge funds and other institutional investors have also modified their holdings of the company. Beach Investment Counsel Inc. PA acquired a new position in Kinetik during the 2nd quarter worth $27,000. Blue Trust Inc. lifted its stake in shares of Kinetik by 244.9% during the third quarter. Blue Trust Inc. now owns 3,801 shares of the company’s stock valued at $158,000 after acquiring an additional 2,699 shares during the period. Harbor Capital Advisors Inc. boosted its holdings in Kinetik by 270.0% in the second quarter. Harbor Capital Advisors Inc. now owns 3,841 shares of the company’s stock valued at $159,000 after acquiring an additional 2,803 shares during the last quarter. CWM LLC increased its position in Kinetik by 2,030.9% in the third quarter. CWM LLC now owns 3,793 shares of the company’s stock worth $172,000 after purchasing an additional 3,615 shares during the period. Finally, Point72 DIFC Ltd bought a new stake in Kinetik during the 2nd quarter worth about $187,000. Institutional investors and hedge funds own 21.11% of the company’s stock. Kinetik Trading Down 0.8 % KNTK stock opened at $61.65 on Friday. The stock has a market cap of $9.71 billion, a PE ratio of 22.75, a price-to-earnings-growth ratio of 2.88 and a beta of 2.91. The stock has a 50-day moving average price of $50.75 and a two-hundred day moving average price of $44.86. Kinetik Holdings Inc. has a 1 year low of $31.73 and a 1 year high of $62.55. Kinetik Increases Dividend The firm also recently declared a quarterly dividend, which was paid on Thursday, November 7th. Shareholders of record on Monday, October 28th were paid a $0.78 dividend. This is a positive change from Kinetik’s previous quarterly dividend of $0.75. This represents a $3.12 annualized dividend and a yield of 5.06%. The ex-dividend date of this dividend was Monday, October 28th. Kinetik’s payout ratio is presently 115.13%. Analyst Ratings Changes KNTK has been the topic of several recent research reports. Royal Bank of Canada raised their target price on shares of Kinetik from $46.00 to $52.00 and gave the company an “outperform” rating in a research note on Wednesday, October 16th. Mizuho lifted their target price on shares of Kinetik from $47.00 to $55.00 and gave the stock an “outperform” rating in a report on Thursday, October 24th. Finally, Barclays increased their price target on Kinetik from $43.00 to $47.00 and gave the company an “equal weight” rating in a research note on Monday, October 14th. Three analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, Kinetik has an average rating of “Moderate Buy” and a consensus price target of $45.71. Check Out Our Latest Analysis on Kinetik Kinetik Company Profile ( Free Report ) Kinetik Holdings Inc operates as a midstream company in the Texas Delaware Basin. The company operates through two segments, Midstream Logistics and Pipeline Transportation. It provides gathering, transportation, compression, processing, stabilization, treating, storage, and transportation services for companies that produce natural gas, natural gas liquids, and crude oil; and water gathering and disposal services. Read More Five stocks we like better than Kinetik 3 Grocery Stocks That Can Help Take a Bite Out of Inflation Vertiv’s Cool Tech Makes Its Stock Red-Hot Dividend Payout Ratio Calculator MarketBeat Week in Review – 11/18 – 11/22 Investing In Automotive Stocks 2 Finance Stocks With Competitive Advantages You Can’t Ignore Want to see what other hedge funds are holding KNTK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kinetik Holdings Inc. ( NASDAQ:KNTK – Free Report ). Receive News & Ratings for Kinetik Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kinetik and related companies with MarketBeat.com's FREE daily email newsletter .

A landmark $600 million deal for a Papua New Guinea team to enter the National Rugby League comes with an escape clause allowing the Australian government to immediately terminate the agreement if PNG strikes a security or policing pact with China or other rival nations over the next decade. Prime Minister Anthony Albanese and PNG Prime Minister James Marape announced at a joint press conference in Sydney that a Port Moresby-based team will enter the NRL from 2028. The PNG team is likely to want Xavier Coates to be its inaugural marquee signing. Credit: Getty “Australia and PNG are the nearest of neighbours and we are the truest of friends,” Albanese said. “We are bound by a history of shared sacrifice and a common commitment to a peaceful, stable and prosperous Pacific. And we are united of course by a love of rugby league. That’s why I’m delighted to announce the Australian government is supporting a PNG team to join the NRL competition from 2028.” “Rugby league is PNG’s national sport and PNG deserves a national team. The new team will belong to the people of PNG and it will call Port Moresby home. It will have millions of people barracking for it from day one.” The leaders hailed the deal as a historic milestone for the PNG-Australia relationship that will bond the nations together and provide a major economic boost to the Pacific’s most populous nation as it seeks to lift much of its population out of poverty. There’s no questioning Papua New Guinea’s passion for rugby league. Credit: Getty “What this is about, isn’t just the elite level,” Albanese said. “This is about the grassroots level. It’s about economic development. It’s about the relationship between our peoples. It provides, as sport often does, an opportunity for people to succeed, not just in sport but in life. “That is why this partnership isn’t just about Papua New Guinea, it’s also about our relationship with the Pacific.” Australian taxpayers will provide $600 million over the next 10 years to help establish the team, with $120 million coming from existing Department of Foreign Affairs and Trade funding. The PNG government has committed to building compound-style accommodation for players and offering tax-free salary benefits to lure star players to its capital, Port Moresby. The Australian and PNG governments have signed a separate agreement on “shared strategic trust” that sits beside the franchise agreement between the NRL, Australia and PNG. The exact terms of the strategic trust agreement are confidential and will not be released to the public. “Today also confirms ... our bilateral security agreement, which was signed just over a year ago in Canberra,” Albanese said. “Since signing that agreement, we’ve made real progress with Australia providing tangible support to PNG’s internal security priorities ... I think that today is a day where people will look back in five years, 10 years, 20 years and see that this was a day where the relationship between our nations was cemented even further into a new level.” Loading While there is no explicit clause granting Australia veto rights over security deals between PNG and other countries, government sources said the NRL agreement was “contingent” on PNG continuing to support the principle that security and policing arrangements are handled by Pacific nations including Australia. The sources, who were not authorised to speak publicly, said the agreement allows the Australian government to withdraw financial support for PNG’s NRL team without supplying a reason until 2035. The NRL would be required to terminate the PNG team’s franchise if the Australian government removes its support under the terms of the agreement. “This is about diplomacy, this is about making Australia safer, this is about securing our status as the security partner of choice in the Pacific,” a senior government source said. The government announced a new treaty earlier this week with Nauru that allows it to block China and other countries from striking any security or telecommunications deals with the tiny Pacific nation in exchange for $140 million in financial support from Australian taxpayers. PNG’s Foreign Minister Justin Tkatchenko told this masthead last week that the agreement has “nothing to do with China” but Australian government officials have insisted there was a security element to the agreement. A separate clause prohibits the NRL from asking the Australian government for more money within or after the 10-year funding period. The logo, colours and name of the PNG team are yet to be determined. One option is for the club to be called the PNG Hunters, the name given to the team that has been playing in the Queensland Cup competition since 2014. Prime Minister Anthony Albanese and PNG counterpart James Marape discussed PNG’s NRL bid while walking the Kokoda Track in April. Credit: Dominic Lorrimer “I want to indicate to everyone here in Australia and back home, we’re not just filling the numbers for Anthony [Albanese] and James [Marape] to feel good,” Marape said. “Far from it. We want to win the competition. Just like the Dolphins did in their first year of entry [in 2023], we will field a very strong team in the first game in 2028. “As South Sydney lives on 100 years on from its birth, this one will live on way after you [Albanese] and me are gone. Our people forever bound in not only a shared love for rugby league, but a shared love for each other.” It remains unclear whether PNG will be the NRL’s 18th or 19th team, given there is a desire to add another side as early as 2027. The NRL remains in negotiations for a Perth-based franchise, which are continuing directly with the WA government after a consortium bid was rejected. Sources said negotiations over the PNG team were up in the air until the May NRL “magic round” in May, when Pacific Minister Pat Conroy and Australian Rugby League chairman Peter V’landys struck an in-principle agreement for a team to enter the competition. One of the likely signing targets for the franchise is Xavier Coates. The Melbourne, Queensland and Australian star was born in Port Moresby, has previously represented Fiji and, given he is only 23 years old, will likely be in his prime when the team enters the NRL. His younger brother, Phillip, is also a rising star who represented the PNG Junior Kumuls in their recent draw with the Australian Schoolboys team. As a sweetener to sign with PNG, players and staff will be granted tax-free status. That will allow a marquee signing on a $1.2 million deal to save up to $550,000 a year. The expansion of the NRL competition is expected to bring more money into the game and the existing clubs have argued for a share. They have been placated by the division of a $60 million license fee, which will come out of the $600 million Australian government payment. Cut through the noise of federal politics with news, views and expert analysis. Subscribers can sign up to our weekly Inside Politics newsletter . Save Log in , register or subscribe to save articles for later. License this article PNG NRL 2024 NRL 2025 Foreign relations China relations China More... Matthew Knott is the foreign affairs and national security correspondent for The Sydney Morning Herald and The Age. Connect via Twitter or Facebook . Adrian Proszenko is the Chief Rugby League Reporter for The Sydney Morning Herald. Connect via Twitter or email . Michael Chammas is a sports reporter with The Sydney Morning Herald Connect via Twitter or email . Most Viewed in Sport LoadingSPRINGFIELD — After more than a month at trial, jurors in Hampden Superior Court today awarded a $10.6 million plaintiff’s verdict in the case of a man suing Big Tobacco for his wife’s fatal smoking addiction. The plaintiff in this case was Kevin Penza, a Walpole man, who sued on behalf of his late wife, Jacqueline, who died from lung cancer at 59 from a cigarette habit she couldn’t quit. He was joined in the lawsuit by the couple’s daughter, Kimberly Breen Penza. The plaintiff’s attorney, Gary Paige of Florida, argued to the jury that Jacqueline Penza was collateral damage from decades of marketing by tobacco companies, whose advertising tactics targeted teens and young adults starting in the 1970s. Paige said Penza began smoking when she was 14. Her addiction was spurred on by free samples that tobacco companies doled out to young people, according to testimony. “She tried over and over and over to quit. She tried New Year’s resolutions, lozenges, nicotine patches ... her family says they’d find her going through dirty ashtrays to find a cigarette with enough tobacco to smoke,” Paige told jurors during opening arguments on Oct. 31. The defendants were R.J. Reynolds Tobacco Co., Philip Morris USA and grocery chains Stop & Shop and Big Y World Class Markets, where Penza often bought the cigarettes that killed her. But by the jury’s verdict, all defendants were shed but R.J. Reynolds. The lawsuit was the first of its kind to be brought in the region. Sprawling litigation over smoking lawsuits has proliferated across the country since the 1990s, when a Tobacco Master Settlement Agreement was reached by between 46 states and major cigarette dealers because of staggering, related health care costs. Since then, people have sued on behalf of relatives who have died as a result of smoking habits, arguing that, for years, cigarette companies for years minimized health risks through slick marketing tactics. Defense lawyer Jason Keehfus, based in Atlanta, told jurors that Penza was a committed smoker who refused to quit despite pleas by her family and doctors. “Jacqueline Penza would say she wanted to quit smoking and five minutes later light up a cigarette. She made her own decisions about smoking,” Keehfus told the jury. Verdict breakdown The defendants were accused of negligent marketing, conspiracy, fraud and breach of marketing. Jurors rejected every claim but conspiracy. RECOMMENDED • masslive .com Asking Eric: I can’t enjoy my porch due to neighbors' pot smoke Dec. 1, 2024, 12:03 a.m. Mass. politics is the secret sauce as Boston PI Spenser returns in new novel | Bay State Briefing Dec. 2, 2024, 5:45 a.m. The panel nonetheless awarded millions in damages over Penza’s health care costs, pain and suffering, wrongful death and punitive damages. The jury awarded:

CRANFORD, N.J. , Dec. 27, 2024 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a specialty biopharmaceutical company focused on the development and commercialization of novel targeted oncology therapies, today reported business and financial results for the fiscal full year ended September 30, 2024 . Fiscal Full Year 2024 Business Highlights and Subsequent Developments Financial Highlights "Reflecting on 2024, Citius Oncology has achieved pivotal milestones that underscore our commitment to advancing cancer therapeutics," stated Leonard Mazur , Chairman and CEO of Citius Oncology. "The FDA's approval of LYMPHIR for the treatment of cutaneous T-cell lymphoma marks a significant advancement in providing new options for patients battling this challenging disease. It is the only targeted systemic therapy approved for CTCL patients since 2018 and the only therapy with a mechanism of action that targets the IL-2 receptor. Additionally, the successful merger forming Citius Oncology, now trading on Nasdaq under the ticker CTOR, strengthens our position in the oncology sector. We expect it to facilitate greater access to capital to fund LYMPHIR's launch and the Company's future growth. With a Phase I investigator-initiated clinical trial combining LYMPHIR with pembrolizumab demonstrating promising preliminary results, indicating potential for enhanced treatment efficacy in recurrent solid tumors, and preliminary results expected from a second investigator trial with CAR-T therapies in 2025, we remain excited about the potential of LYMPHIR as a combination immunotherapy." "These accomplishments reflect the dedication of our team and the trust of our investors. As we look ahead, we remain steadfast in our mission to develop innovative therapies that improve the lives of cancer patients worldwide," added Mazur. FULL YEAR 2024 FINANCIAL RESULTS: Research and Development (R&D) Expenses R&D expenses were $4.9 million for the full year ended September 30, 2024 , compared to $4.2 million for the full year ended September 30, 2023 . The increase reflects development activities completed for the resubmission of the Biologics License Application of LYMPHIR in January 2024 , which were associated with the complete response letter remediation. General and Administrative (G&A) Expenses G&A expenses were $8.1 million for the full year ended September 30, 2024 , compared to $5.9 million for the full year ended September 30, 2023 . The increase was primarily due to costs associated with pre-commercial and commercial launch activities of LYMPHIR including market research, marketing, distribution and drug product reimbursement from health plans and payers. Stock-based Compensation Expense For the full year ended September 30, 2024 , stock-based compensation expense was $7.5 million as compared to $2.0 million for the prior year. The primary reason for the $5.5 million increase was due to the amounts being realized over 12 months in the year ended September 30, 2024 , as compared to three months post-plan adoption in the year ended September 30, 2023 . Net loss Net loss was $21.1 million , or ($0.31) per share for the year ended September 30, 2024 , compared to a net loss of $12.7 million , or ($0.19) per share for the year ended September 30, 2023 . The $8.5 million increase in net loss was primarily due to the increase in our operating expenses. About Citius Oncology, Inc. Citius Oncology specialty is a biopharmaceutical company focused on developing and commercializing novel targeted oncology therapies. In August 2024 , its primary asset, LYMPHIR, was approved by the FDA for the treatment of adults with relapsed or refractory CTCL who had had at least one prior systemic therapy. Management estimates the initial market for LYMPHIR currently exceeds $400 million , is growing, and is underserved by existing therapies. Robust intellectual property protections that span orphan drug designation, complex technology, trade secrets and pending patents for immuno-oncology use as a combination therapy with checkpoint inhibitors would further support Citius Oncology's competitive positioning. Citius Oncology is a publicly traded subsidiary of Citius Pharmaceuticals. For more information, please visit www.citiusonc.com Forward-Looking Statements This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius Oncology. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "plan," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated, and, unless noted otherwise, that apply to Citius Oncology are: our ability to raise additional money to fund our operations for at least the next 12 months as a going concern; our ability to commercialize LYMPHIR and any of our other product candidates that may be approved by the FDA; the estimated markets for our product candidates and the acceptance thereof by any market; the ability of our product candidates to impact the quality of life of our target patient populations; our dependence on third-party suppliers; our ability to procure cGMP commercial-scale supply; risks related to research using our assets but conducted by third parties; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; market and other conditions; risks related to our growth strategy; patent and intellectual property matters; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; government regulation; competition; as well as other risks described in our Securities and Exchange Commission ("SEC") filings. These risks have been and may be further impacted by any future public health risks. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our SEC filings which are available on the SEC's website at www.sec.gov , including in Citius Oncology's Annual Report on Form 10-K for the year ended September 30, 2024 , filed with the SEC on December 27, 2024 , as updated by our subsequent filings with the SEC. These forward-looking statements speak only as of the date hereof, and we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law. Investor Contact: Ilanit Allen ir@citiuspharma.com 908-967-6677 x113 Media Contact: STiR-communications Greg Salsburg Greg@STiR-communications.com -- Financial Tables Follow – CITIUS ONCOLOGY, INC. CONSOLIDATED BALANCE SHEETS SEPTEMBER 30, 2024 AND 2023 2024 2023 Current Assets: Cash and cash equivalents $ 112 $ — Inventory 8,268,766 — Prepaid expenses 2,700,000 7,734,895 Total Current Assets 10,968,878 7,734,895 Other Assets: In-process research and development 73,400,000 40,000,000 Total Other Assets 73,400,000 40,000,000 Total Assets $ 84,368,878 $ 47,734,895 LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities: Accounts payable $ 3,711,622 $ 1,289,045 License payable 28,400,000 — Accrued expenses — 259,071 Due to related party 588,806 19,499,119 Total Current Liabilities 32,700,429 21,047,235 Deferred tax liability 1,728,000 1,152,000 Note payable to related party 3,800,111 — Total Liabilities 38,228,540 22,199,235 Stockholders' Equity: Preferred stock - $0.0001 par value; 10,000,000 shares authorized: no shares issued and outstanding — — Common stock - $0.0001 par value; 100,000,000; 71,552,402 and 67,500,000 shares issued and outstanding at September 30, 2024 and 2023, respectively 7,155 6,750 Additional paid-in capital 85,411,771 43,658,750 Accumulated deficit (39,278,587) (18,129,840) Total Stockholders' Equity 46,140,339 25,535,660 Total Liabilities and Stockholders' Equity $ 84,368,878 $ 47,734,895 CITIUS ONCOLOGY, INC. CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE YEARS ENDED SEPTEMBER 30, 2024 AND 2023 2024 2023 Revenues $ — $ — Operating Expenses: Research and development 4,925,001 4,240,451 General and administrative 8,148,929 5,915,290 Stock-based compensation – general and administrative 7,498,817 1,965,500 Total Operating Expenses 20,572,747 12,121,241 Loss before Income Taxes (20,572,747) (12,121,241) Income tax expense 576,000 576,000 Net Loss $ (21,148,747) $ (12,697,241) Net Loss Per Share – Basic and Diluted $ (0.31) $ (0.19) Weighted Average Common Shares Outstanding – Basic and Diluted 68,053,607 67,500,000 CITIUS ONCOLOGY, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE YEARS ENDED SEPTEMBER 30, 2024 AND 2023 2024 2023 Cash Flows From Operating Activities: Net loss $ (21,148,747) $ (12,697,241) Adjustments to reconcile net loss to net cash provided by operating activities: Stock-based compensation expense 7,498,817 1,965,500 Deferred income tax expense 576,000 576,000 Changes in operating assets and liabilities: Inventory (2,133,871) - Prepaid expenses (1,100,000) (5,044,713) Accounts payable 2,422,577 1,196,734 Accrued expenses (259,071) (801,754) Due to related party 14,270,648 14,805,474 Net Cash Provided By Operating Activities 126,353 - Cash Flows From Investing Activities: License payment (5,000,000) - Net Cash Used In Investing Activities (5,000,000) - Cash Flows From Financing Activities: Cash contributed by parent 3,827,944 - Merger, net (2,754,296) - Proceeds from issuance of note payable to related party 3,800,111 - Net Cash Provided By Financing Activities 4,873,759 - Net Change in Cash and Cash Equivalents 112 - Cash and Cash Equivalents – Beginning of Year - - Cash and Cash Equivalents – End of Year $ 112 $ - Supplemental Disclosures of Cash Flow Information and Non-cash Activities: IPR&D Milestones included in License Payable $ 28,400,000 $A massive stampede of teens pushed and shoved their way into a shop after they were invited to ransack the store. Dozens of young men could be seen running towards the shop StreetX in Perth on Boxing Day , and in the mayhem people were pictured with cuts and bruises. Store owner and founder of the StreetX label, Daniel Bradshaw, had encouraged people to come down and “rob” his store as he planned to give away hundreds of t-shirts. He is known for his high profile marketing campaigns and this certainly attracted attention with youngsters arriving by 11pm on Christmas Day to be first in the queue when the shop opened at 9am the next day. Footage shows people bursting through the doors of the shop on Shafto Lane, with a pile of bodies at the front door as people were knocked over - but fortunately nobody was badly injured. There was even one person who had turned up well prepared wearing a bicycle helmet and wearing shoulder pads. “We wanted to give our customers something fun. We made the entire store free. There were 400 items to ‘steal’,” he told The West Australian . “It was gone in 30 seconds. It was crazy. Just a stampede of people.” He added that the police this year were “fine” with what happened. Clips shared on social media also showed bizarre scenes of people drinking milk and raw eggs from shoes, throwing food at each other and also shaving heads. Last year Mr Bradshaw said there had been trouble with the police while they had filmed a mock robbery and that this time around they had been more careful. “We always do a Boxing Day sale. Last year, we did a give-away out the back of a truck. This year we wanted something that ideally wouldn’t get us in trouble,” he said. “Cops came today and they were fine with it. Touch wood no one got injured.” But not everybody was happy and one mum complained that her son had been “punched in the head” during the stampede. "My son was punched in the head and had his items stolen by a young adult thug," she wrote on Instagram . "I get what you're trying to do but not having any control over violence is just not ok."

Tech firms are escalating their push to turn every outfit spotted on social media into an instant shopping opportunity, with startup Aesthetic launching the latest entry into the artificial intelligence (AI)-powered clothing recognition field. The launch adds to the growing competition in “see-now-buy-now” fashion AI technology, where established players like Google Lens and Pinterest already offer tools to help users identify and purchase clothing they discover while scrolling through their feeds. Aesthetic has gone through a seed funding round led by Craft Ventures, according to an Oct. 29 TechCrunch report . The startup’s founder told the publication that its technology can identify specific garments with 90% accuracy across major fashion brands and retailers. The field has seen increasing investment as social media platforms race to add shopping features. Pinterest recently expanded its visual search capabilities to identify multiple items in a single image, while Google has partnered with retailers to integrate its Lens technology directly into their apps. See also: Google’s Revamped Platform Brings AI Insights, Price Comparisons to In-Store and Online Retail “At a time when influencer marketing is rapidly optimizing lead generation across visual social platforms like TikTok and Instagram, the rise of ‘see it, buy it’ technology can lead to new opportunities for brands to appeal to their target audience by supplying wardrobes to carefully selected influencer accounts,” Tom South , director of organic and web at Epos Now , told PYMNTS. Aesthetic’s technology lets users search with screenshots or photos, analyzing an image to identify specific clothing items and matching them to similar products. Unlike broader visual search tools, the company says it focuses exclusively on fashion, training its AI to recognize details like necklines, sleeve lengths and fabric patterns. The use of AI for search isn’t entirely new. Google Lens launched a feature in 2019 called “style ideas,” letting users find outfit inspirations by analyzing clothing through photos. This feature helps shoppers see how others style similar items or match existing wardrobe pieces. Snap, Search, Shop AI-powered visual search is changing eCommerce by shifting how consumers shop. Instead of typing queries, customers use images to find products intuitively. Amazon ’s app lets users snap a photo to discover similar items on their platform, simplifying the shopping experience. Pinterest’s visual tools enable users to identify and buy products directly from images. Fashion retailers like ASOS have added a visual search feature to their apps, allowing customers to upload photos to find matching clothing items. “I think this type of AI visual shopping search makes it very convenient for consumers,” Alex Smith , the founder of A Couple Consumers , told PYMNTS. “People can view content, see what people are wearing or what products they are using, and instantly know, assuming the software is spot-on, which product it is. Then, obviously, they can purchase it or add it to the cart when they’re ready to buy.” In the past few months, visual search AI has made notable strides in the eCommerce world. Miros , an AI-powered visual search company from Tallinn, Estonia, last month secured 6 million euros (about $6.3 million) in pre-Series A funding to advance its technology. This innovation aims to tackle a massive $2 trillion global issue: product loss due to poor text-based searches. By enabling shoppers to find items using images instead of text, it greatly enhances the online shopping experience. At the same time, these technological developments are reshaping personal style discovery, enhancing the influence of social media personalities and providing brands with new collaboration opportunities. “Innovations in personal style discovery will generate even more power for influencers and improve the options available to brands looking to use social media personalities to promote products,” South said. “From shipping garments as freebies to structured wardrobes provided for events, this new frontier for instant shopping opportunities could be a watershed moment for influencer marketing ROI.”Empowered Funds LLC lifted its position in shares of Johnson Outdoors Inc. ( NASDAQ:JOUT – Free Report ) by 5.4% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 18,411 shares of the company’s stock after purchasing an additional 938 shares during the quarter. Empowered Funds LLC owned approximately 0.18% of Johnson Outdoors worth $666,000 as of its most recent filing with the Securities and Exchange Commission. A number of other institutional investors and hedge funds have also modified their holdings of the company. Vanguard Group Inc. lifted its position in Johnson Outdoors by 13.9% in the first quarter. Vanguard Group Inc. now owns 346,115 shares of the company’s stock worth $15,959,000 after purchasing an additional 42,314 shares during the period. Deprince Race & Zollo Inc. lifted its holdings in shares of Johnson Outdoors by 35.8% during the 2nd quarter. Deprince Race & Zollo Inc. now owns 223,814 shares of the company’s stock worth $7,829,000 after acquiring an additional 59,016 shares during the period. Skylands Capital LLC lifted its holdings in shares of Johnson Outdoors by 43.7% during the 2nd quarter. Skylands Capital LLC now owns 161,900 shares of the company’s stock worth $5,663,000 after acquiring an additional 49,200 shares during the period. Allspring Global Investments Holdings LLC boosted its position in shares of Johnson Outdoors by 33.6% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 75,530 shares of the company’s stock valued at $2,734,000 after acquiring an additional 19,013 shares in the last quarter. Finally, Kennedy Capital Management LLC increased its stake in Johnson Outdoors by 66.1% in the first quarter. Kennedy Capital Management LLC now owns 73,026 shares of the company’s stock valued at $3,367,000 after acquiring an additional 29,065 shares during the period. 64.05% of the stock is currently owned by institutional investors. Analyst Upgrades and Downgrades Separately, StockNews.com upgraded shares of Johnson Outdoors from a “sell” rating to a “hold” rating in a research note on Thursday, August 8th. Johnson Outdoors Price Performance Shares of NASDAQ:JOUT opened at $33.37 on Friday. The business’s fifty day moving average price is $34.27 and its two-hundred day moving average price is $35.59. Johnson Outdoors Inc. has a fifty-two week low of $31.60 and a fifty-two week high of $55.30. The stock has a market capitalization of $343.71 million, a price-to-earnings ratio of -41.20, a price-to-earnings-growth ratio of 1.61 and a beta of 0.71. Johnson Outdoors Announces Dividend The company also recently announced a quarterly dividend, which was paid on Wednesday, October 23rd. Stockholders of record on Wednesday, October 9th were issued a $0.33 dividend. This represents a $1.32 annualized dividend and a dividend yield of 3.96%. The ex-dividend date was Wednesday, October 9th. Johnson Outdoors’s payout ratio is -162.96%. About Johnson Outdoors ( Free Report ) Johnson Outdoors Inc designs, manufactures, and markets seasonal and outdoor recreational products for fishing worldwide. It operates through four segments: Fishing, Camping, Watercraft Recreation, and Diving. The Fishing segment offers electric motors for trolling, marine battery chargers, and shallow water anchors; sonar and GPS equipment for fish finding, navigation, and marine cartography; and downriggers for controlled-depth fishing. Featured Stories Five stocks we like better than Johnson Outdoors Compound Interest and Why It Matters When Investing Vertiv’s Cool Tech Makes Its Stock Red-Hot Buy P&G Now, Before It Sets A New All-Time High MarketBeat Week in Review – 11/18 – 11/22 What is the S&P/TSX Index? 2 Finance Stocks With Competitive Advantages You Can’t Ignore Receive News & Ratings for Johnson Outdoors Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson Outdoors and related companies with MarketBeat.com's FREE daily email newsletter .